Program Overview
This CME program will highlight recent advances in the treatment and management of patients with Parkinson’s disease (PD), covering topics such as OFF episodes, deep brain stimulation (DBS) and psychosis. The expert faculty, led by Dr. Stuart Isaacson, will first delve into OFF episodes, analyzing the causes of OFF periods, and the impact on quality of life and patient perceptions, among other topics. Next, the role of deep brain stimulation in PD as well as the current available systems will be reviewed, and clinical relevance debated. Finally, the faculty will highlight best practices for the treatment of Parkinson’s disease psychosis, addressing common patient misconceptions. This CME activity will better equip clinicians with current data to improve outcomes and quality of life in patients with Parkinson’s disease.
Target Audience
Neurologists, primary care physicians and other healthcare professionals involved in the management of patients with movement disorders
Learning Objectives
- Understand the pathophysiology and treatment options for OFF episodes in Parkinson’s disease
- Review the role of deep brain stimulation to improve outcomes in patients with Parkinson’s disease
- Analyze the disease burden and therapeutic options to manage patients with Parkinson’s disease psychosis
Agenda
I. Therapeutic Advances in the Treatment of OFF Episodes in PD – Stuart Isaacson, MD
II. The Role of Deep Brain Stimulation in Parkinson’s Disease – Rajesh Pahwa, MD
III. Best Practices for the Treatment of Parkinson’s Disease Psychosis – Daniel Kremens, MD, JD
IV. Interactive Panel Discussion – Stuart Isaacson, MD and Expert Faculty
Chair
Stuart Isaacson, MD (Course Chair)
Director, Florida Institute for Neurodegenerative Disorders
Parkinson’s Disease and Movement Disorders Center of Boca Raton
Alzheimer’s and Memory Disorders Center of South Florida
Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Boca Raton, Florida
Faculty
Daniel Kremens, MD, JD, FAAN
Associate Professor of Neurology
Sidney Kimmel Medical College at Thomas Jefferson University
Co-Director of the Parkinson’s Disease and Movement Disorders Division
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania
Rajesh Pahwa, MD, FAAN
Laverne And Joyce Rider Professor of Neurology
Chief, Parkinson’s and Movement Disorder Center
University of Kansas Medical Center
Kansas City, Kansas
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Stuart Isaacson, MD (Course Chair)
|
Consultant/Advisor: AbbVie Inc.; Acadia Pharmaceuticals; Acorda Therapeutics; Adamas Pharmaceuticals; Addex Pharmaceuticals Ltd.; Allergan; Amneal Pharmaceuticals; Britannia Pharmaceuticals; Centogene; Cerecor, Inc; GE Healthcare; Global Kinetics Pty Ltd.; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Merz Pharma; Keifrx; Neurocrine Biosciences, Inc.; Neuroderm; Pharma Two B Ltd.; Revance Therapeutics Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; UCB
Grant/Research Support: AbbVie Inc.; Acadia Pharmaceuticals; Acorda Therapeutics; Adamas Pharmaceuticals; Addex Pharmaceuticals Ltd.; Amneal Pharmaceuticals; Aptinyx Inc.; Axial Therapeutics, Inc.; Benevolent; Biogen; Biohaven Pharmaceuticals; Britannia Pharmaceuticals; Cala Health; Centogene; Cerecor, Inc; Cerevance; Cerevel Therapeutics; Chase Therapeutics; Eli Lilly and Company; Enterin Inc.; Global Kinetics Pty Ltd.; Jazz Pharmaceuticals, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Neurocrine Biosciences, Inc.; Neuroderm; Pharma Two B Ltd.; Revance Therapeutics Inc.; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; UCB Speakers Bureau: AbbVie Inc.; Acadia Pharmaceuticals; Acorda Therapeutics; Adamas Pharmaceuticals; Addex Pharmaceuticals Ltd.; Amneal Pharmaceuticals; GE Healthcare; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Neurocrine Biosciences, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; UCB |
| Daniel Kremens, MD, JD, FAAN
|
Consultant/Advisor: AbbVie Inc.; Acadia Pharmaceuticals; Acorda Therapeutics; Adamas Pharmaceuticals; Allergan; Amneal Pharmaceuticals; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Merz Pharma; Neurocrine Biosciences, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; US WorldMeds
Grant/Research Support: Revance Therapeutics Inc.; Voyager Therapeutics Speakers Bureau: Acadia Pharmaceuticals; Acorda Therapeutics; Adamas Pharmaceuticals; Amneal Pharmaceuticals; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Neurocrine Biosciences, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; US WorldMeds |
| Rajesh Pahwa, MD, FAAN | Consultant/Advisor: Abbot; AbbVie Inc.; Acadia Pharmaceuticals; Acorda Therapeutics; Adamas Pharmaceuticals; Amneal Pharmaceuticals; Britannia Pharmaceuticals; Cala Health; Global Kinetics Pty Ltd.; Impel NeuroPharma, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; Lundbeck; Mitsubishi Tanabe Pharma America; Neurocrine Biosciences, Inc.; Orbis Biosciences, Inc.; PhotoPharmics, Inc.; Prilenia Therapeutics; Sunovion Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.; US WorldMeds
Grant/Research Support: Abbot; AbbVie Inc.; Addex Pharmaceuticals Ltd.; Biogen; Biohaven Pharmaceuticals; Boston Scientific Corporation; EIP Pharma; Eli Lilly and Company; Global Kinetics Pty Ltd.; Impax Laboratories; Intec Pharma Ltd.; Neuroderm; Neuraly; Pharma Two B Ltd.; Prilenia Therapeutics; Roche; SIS Medical; Sun Pharmaceutical Industries Ltd.; Sunovion Pharmaceuticals; Theranexus; Theravance Biopharma; US WorldMeds; Voyager Therapeutics |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity is supported by independent educational grants from Abbot, Acadia Pharmaceuticals and Acorda Therapeutics.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Abbot, Acadia Pharmaceuticals and Acorda Therapeutics do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
